Endo International PLC (NASDAQ:ENDP) shares are trading lower by 16.86% to $0.39 after the company provided top-line results from its Phase 2 study of CCH in patients with adhesive capsulitis of the shoulder, saying "the difference compared to those study participants receiving placebo was not statistically significant."
"We are disappointed in the study outcome, and based on these data, we will be reevaluating our path forward for CCH for the treatment of adhesive capsulitis of the shoulder. We will continue focusing on our pipeline, including with respect to other potential CCH indications," said James P. Tursi, M.D., Executive Vice President, Global Research & Development at Endo.
